Trial: 201911082

A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA)

Phase

I/II

Principal Investigator

Ma, Cynthia

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov